2023 Novel Drug Approvals (3/6/24)

Number, % = Number Respondents, % of Total

Objective 1: Recall the new molecular entities

approved by the Food and Drug Administration (FDA)
in 2023

9, 15%
Excellent
Very Good
Good
19, 33% 30, 52%
Fair
Poor

Objective 2: Recognize the indications and drug

classes of the new drugs

9, 15%
Excellent
Very Good
Good
30, 52%
19, 33% Fair
Poor

Objective 3: Identify common adverse events,

available dosage forms, and clinical pearls of the new
drugs

9, 15%
Excellent
Very Good
Good
19, 33% 30, 52%
Fair
Poor
 2023 Novel Drug Approvals (3/6/24)

The activity met my educational needs.

4, 7%

Strongly Agree
Agree
29, 50% Neutral
25, 43% Disagree
Strongly Disagree

The speaker was organized in their

presentation.

Strongly Agree
Agree
25, 43%
Neutral
33, 57% Disagree
Strongly Disagree

The speaker provided evidence-based

information.

1, 2%

Strongly Agree
Agree
25, 43% Neutral
32, 55%
Disagree
Strongly Disagree
 2023 Novel Drug Approvals (3/6/24)

The learning assessment adequately

assessed my learning of the objectives.

6, 10%

Strongly Agree
Agree
28, 48%
Neutral
24, 42% Disagree
Strongly Disagree

The delivery format for the activity

worked well for the program objectives.

3, 5%

Strongly Agree
Agree
28, 48%
Neutral
27, 47% Disagree
Strongly Disagree

Overall, this was a high-quality program

4, 7%

Strongly Agree
Agree
28, 48%
Neutral
26, 45% Disagree
Strongly Disagree
 2023 Novel Drug Approvals (3/6/24)

Will the information presented cause you

to change how you practice or care for
patients?

Yes
28, 48% 21, 36%
No
Not Sure

9, 16%

Please note any bias or commercialism in

the presentation.

None
Yes

58, 100%

Qualitative data is on next page.

 2023 Novel Drug Approvals (3/6/24)

What other topics would you like to see in upcoming CE presentations?

- New treatments of MS
- Stroke, Sepsis, Pancreatitis
- similar
- burnout strategies for pharmacists
- Understanding MABs
- Antimicrobial
- Vaccines
- Drug Shortages, Contract Load/Price discrepancies solutions
- treatment of heart failure. follow up with more new drug approvals

Additional Comments

- great Presentations!
- Very boring, monotone presentation. I know it's not the most exciting topic, but it was very hard to get into. A lot of
reading off the slides which we are all able to do
- Great Presentation!
- Thank you
- great presentation of a difficult topic!
- Approved Medications slide should have included the generic names of the products.
- Excellent presentation. The medications presented were a good selection from the many new drugs available. Thank you!
- Would have liked to see a pharmacoeconomic/value analysis of these newer meds included. May be good to have another
presentation focused on new oncology drugs, focusing on the ones likely to make the biggest impact in patient care and on
economics.